ICON Portfolio of AI Tools Drives Clinical Trial Efficiencies
ICON plc, (
NASDAQICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portfolio of artificial intelligence (AI) tools that deliver efficiencies across the clinical trial process, including study startup, document management, resource forecasting and metrics reporting.
ICON plc Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call
ICON plc, (
NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will release financial results for the fourth quarter and full year 2024 results after the market closes on Wednesday, February 19, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, February 20, 2025 at 8:00am ET.
ICON Issues Financial Guidance for Full Year 2025
ICON plc, (
NASDAQICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2025. For the full year 2025, revenue is expected to be in the range of $8,050 - $8,650 million, representing growth of approximately 1% at the midpoint and adjusted earnings per share* is expected to be in the range of $13.00 - $15.00, which is flat over the expected full year 2024 adjusted earnings per share guidance midpoint.
Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey
ICON plc, (
NASDAQICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer's, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial methodologies.
ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ICON plc, (
NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 3.45pm PST.
ICON and Its Employees Celebrated for Excellence in the Field of Clinical Research
ICON plc, (
NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024.
ICON Announces Appointment of Chief Operating Officer
ICON plc (
NASDAQICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Barry Balfe as Chief Operating Officer (COO).
ICON Survey Highlights Sustained Investment in AI and Digital R&D Innovation, Tempered by Siloed Adoption
ICON plc, (
NASDAQICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent global survey of 101 biotech and pharma professionals across Europe and North America to understand the trajectory of AI and digital innovation adoption within clinical research.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of ICON Public Limited Company (“Icon” or the “Company”) (
NASDAQICLR) investors concerning the Company’s possible violations of the federal securities laws.
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors
Law Offices of Howard G. Smith continues its investigation on behalf of ICON Public Limited Company (“Icon” or the “Company”) (
NASDAQICLR) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors
The Law Offices of Frank R. Cruz continues its investigation of ICON Public Limited Company (“Icon” or the “Company”) (
NASDAQICLR) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of ICON Public Limited Company (“Icon” or the “Company”) (
NASDAQICLR) investors concerning the Company’s possible violations of the federal securities laws.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of ICON Public Limited Company (“Icon” or the “Company”) (
NASDAQICLR) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz Announces Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of ICON Public Limited Company (“Icon” or the “Company”) (
NASDAQICLR) on behalf of investors concerning the Company’s possible violations of federal securities laws.
ICON plc to Present at the Jefferies London Healthcare Conference
ICON plc, (
NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc and Mr. Nigel Clerkin, CFO of ICON plc will present at the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:00am GMT.
ICON Reports Third Quarter 2024 Results
ICON plc (
NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the third quarter ended September 30, 2024.
ICON plc Schedules Third Quarter 2024 Earnings Conference Call
ICON plc (
NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the third quarter 2024 after the market closes on Wednesday, October 23, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, October 24, 2024 at 8:00am ET.
ICON Survey Highlights Scale of Focus on Precision Therapies in Increasingly Complex Oncology Landscape
ICON plc, (
NASDAQICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent survey of over 100 professionals engaged in oncology drug development to understand the current state of emerging oncology treatment development, including the associated clinical trial dynamics. Respondents acknowledged that much focus has been accorded to emerging oncology treatments; however, as of yet, there are varied views on the degree to which these precision approaches will improve patient outcomes.
ICON plc to Present at the Baird 2024 Global Healthcare Conference
ICON plc, (
NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Baird 2024 Global Healthcare Conference on Tuesday, September 10, 2024 at 3:45 pm ET.
ICON Announces Appointment of New Chief Financial Officer
ICON plc (
NASDAQICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO).
ICON Reports Second Quarter 2024 Results
ICON plc (
NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the second quarter ended June 30, 2024.
ICON announces results of Annual General Meeting and changes to the Board of Directors
ICON plc (
NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 23, 2024 were duly passed by shareholders. ICON also confirmed that following the conclusion of the company's AGM, Joan Garahy retired as a non-executive director and announced that Anne Whitaker was appointed as a non-executive director.
ICON Recognised for Leadership Position in Clinical Research Industry and as Socially Responsible Employer
ICON plc, (
NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2024 with a number of leading business and industry awards recognising the company’s leadership position in the clinical research industry, in addition to its efforts in inclusion, sustainability and as an employer of choice.
ICON plc Schedules Second Quarter 2024 Earnings Conference Call
ICON plc (
NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, July 24, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, July 25, 2024 at 8:00am ET.
ICON plc to Present at the Jefferies Global Healthcare Conference
ICON plc (
NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 1:30pm ET.
